nodes	percent_of_prediction	percent_of_DWPC	metapath
Risperidone—KCNH2—Sunitinib—pancreatic cancer	0.0411	0.0761	CbGbCtD
Risperidone—CYP3A7—Tamoxifen—pancreatic cancer	0.0375	0.0695	CbGbCtD
Risperidone—CYP3A7-CYP3A51P—Tamoxifen—pancreatic cancer	0.0375	0.0695	CbGbCtD
Risperidone—CYP3A7-CYP3A51P—Irinotecan—pancreatic cancer	0.0288	0.0533	CbGbCtD
Risperidone—CYP3A7—Irinotecan—pancreatic cancer	0.0288	0.0533	CbGbCtD
Risperidone—CYP3A5—Tamoxifen—pancreatic cancer	0.0282	0.0521	CbGbCtD
Risperidone—CYP3A5—Erlotinib—pancreatic cancer	0.0239	0.0443	CbGbCtD
Risperidone—CYP3A5—Irinotecan—pancreatic cancer	0.0216	0.04	CbGbCtD
Risperidone—CYP3A7—Docetaxel—pancreatic cancer	0.0211	0.0391	CbGbCtD
Risperidone—CYP3A7-CYP3A51P—Docetaxel—pancreatic cancer	0.0211	0.0391	CbGbCtD
Risperidone—CYP3A7-CYP3A51P—Sunitinib—pancreatic cancer	0.021	0.0389	CbGbCtD
Risperidone—CYP3A7—Sunitinib—pancreatic cancer	0.021	0.0389	CbGbCtD
Risperidone—ABCB1—Tamoxifen—pancreatic cancer	0.0183	0.0339	CbGbCtD
Risperidone—CYP2D6—Tamoxifen—pancreatic cancer	0.0173	0.032	CbGbCtD
Risperidone—CYP3A5—Docetaxel—pancreatic cancer	0.0158	0.0293	CbGbCtD
Risperidone—ABCB1—Gemcitabine—pancreatic cancer	0.0158	0.0292	CbGbCtD
Risperidone—CYP3A5—Sunitinib—pancreatic cancer	0.0158	0.0292	CbGbCtD
Risperidone—ABCB1—Erlotinib—pancreatic cancer	0.0156	0.0288	CbGbCtD
Risperidone—CYP2D6—Erlotinib—pancreatic cancer	0.0147	0.0272	CbGbCtD
Risperidone—ABCB1—Irinotecan—pancreatic cancer	0.0141	0.026	CbGbCtD
Risperidone—CYP3A4—Tamoxifen—pancreatic cancer	0.011	0.0203	CbGbCtD
Risperidone—ABCB1—Docetaxel—pancreatic cancer	0.0103	0.0191	CbGbCtD
Risperidone—ABCB1—Sunitinib—pancreatic cancer	0.0103	0.019	CbGbCtD
Risperidone—CYP3A4—Erlotinib—pancreatic cancer	0.00934	0.0173	CbGbCtD
Risperidone—CYP3A4—Irinotecan—pancreatic cancer	0.00843	0.0156	CbGbCtD
Risperidone—ABCB1—Doxorubicin—pancreatic cancer	0.00769	0.0142	CbGbCtD
Risperidone—CYP2D6—Doxorubicin—pancreatic cancer	0.00724	0.0134	CbGbCtD
Risperidone—CYP3A4—Docetaxel—pancreatic cancer	0.00618	0.0114	CbGbCtD
Risperidone—CYP3A4—Sunitinib—pancreatic cancer	0.00615	0.0114	CbGbCtD
Risperidone—HTR7—enteric nervous system—pancreatic cancer	0.00527	0.36	CbGeAlD
Risperidone—CYP3A4—Doxorubicin—pancreatic cancer	0.00461	0.00852	CbGbCtD
Risperidone—HTR2A—enteric nervous system—pancreatic cancer	0.00328	0.224	CbGeAlD
Risperidone—H1F0—islet of Langerhans—pancreatic cancer	0.000816	0.0558	CbGeAlD
Risperidone—H1F0—pancreas—pancreatic cancer	0.000573	0.0392	CbGeAlD
Risperidone—H1F0—digestive system—pancreatic cancer	0.00049	0.0335	CbGeAlD
Risperidone—KCNH2—islet of Langerhans—pancreatic cancer	0.000469	0.032	CbGeAlD
Risperidone—CYP3A5—islet of Langerhans—pancreatic cancer	0.000387	0.0265	CbGeAlD
Risperidone—ADRA2A—islet of Langerhans—pancreatic cancer	0.000369	0.0252	CbGeAlD
Risperidone—HTR2B—digestive system—pancreatic cancer	0.000353	0.0241	CbGeAlD
Risperidone—ADRA2C—pancreas—pancreatic cancer	0.000325	0.0222	CbGeAlD
Risperidone—HTR7—digestive system—pancreatic cancer	0.000302	0.0207	CbGeAlD
Risperidone—CYP3A5—pancreas—pancreatic cancer	0.000272	0.0186	CbGeAlD
Risperidone—ADRA2A—pancreas—pancreatic cancer	0.000259	0.0177	CbGeAlD
Risperidone—CYP3A5—digestive system—pancreatic cancer	0.000232	0.0159	CbGeAlD
Risperidone—HRH1—digestive system—pancreatic cancer	0.000226	0.0154	CbGeAlD
Risperidone—ABCB1—islet of Langerhans—pancreatic cancer	0.000206	0.0141	CbGeAlD
Risperidone—HTR2A—digestive system—pancreatic cancer	0.000188	0.0129	CbGeAlD
Risperidone—CYP3A4—digestive system—pancreatic cancer	0.000174	0.0119	CbGeAlD
Risperidone—CYP2D6—digestive system—pancreatic cancer	0.000172	0.0117	CbGeAlD
Risperidone—ABCB1—pancreas—pancreatic cancer	0.000145	0.00988	CbGeAlD
Risperidone—ABCB1—digestive system—pancreatic cancer	0.000123	0.00844	CbGeAlD
Risperidone—Agranulocytosis—Epirubicin—pancreatic cancer	7.28e-05	0.000246	CcSEcCtD
Risperidone—Pneumonia—Doxorubicin—pancreatic cancer	7.26e-05	0.000245	CcSEcCtD
Risperidone—Shock—Docetaxel—pancreatic cancer	7.26e-05	0.000245	CcSEcCtD
Risperidone—Nervous system disorder—Docetaxel—pancreatic cancer	7.23e-05	0.000244	CcSEcCtD
Risperidone—Pruritus—Fluorouracil—pancreatic cancer	7.23e-05	0.000244	CcSEcCtD
Risperidone—Thrombocytopenia—Docetaxel—pancreatic cancer	7.22e-05	0.000244	CcSEcCtD
Risperidone—Drowsiness—Doxorubicin—pancreatic cancer	7.22e-05	0.000244	CcSEcCtD
Risperidone—Infestation NOS—Doxorubicin—pancreatic cancer	7.22e-05	0.000244	CcSEcCtD
Risperidone—Infestation—Doxorubicin—pancreatic cancer	7.22e-05	0.000244	CcSEcCtD
Risperidone—Tachycardia—Docetaxel—pancreatic cancer	7.2e-05	0.000243	CcSEcCtD
Risperidone—Skin disorder—Docetaxel—pancreatic cancer	7.16e-05	0.000242	CcSEcCtD
Risperidone—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	7.15e-05	0.000242	CcSEcCtD
Risperidone—Bradycardia—Epirubicin—pancreatic cancer	7.13e-05	0.000241	CcSEcCtD
Risperidone—Diarrhoea—Gemcitabine—pancreatic cancer	7.11e-05	0.00024	CcSEcCtD
Risperidone—Renal failure—Doxorubicin—pancreatic cancer	7.09e-05	0.000239	CcSEcCtD
Risperidone—Neuropathy peripheral—Doxorubicin—pancreatic cancer	7.07e-05	0.000239	CcSEcCtD
Risperidone—Dizziness—Irinotecan—pancreatic cancer	7.05e-05	0.000238	CcSEcCtD
Risperidone—Haemoglobin—Epirubicin—pancreatic cancer	7.04e-05	0.000238	CcSEcCtD
Risperidone—Stomatitis—Doxorubicin—pancreatic cancer	7.03e-05	0.000237	CcSEcCtD
Risperidone—Jaundice—Doxorubicin—pancreatic cancer	7.03e-05	0.000237	CcSEcCtD
Risperidone—Anorexia—Docetaxel—pancreatic cancer	7.03e-05	0.000237	CcSEcCtD
Risperidone—Rhinitis—Epirubicin—pancreatic cancer	7.02e-05	0.000237	CcSEcCtD
Risperidone—Conjunctivitis—Doxorubicin—pancreatic cancer	7.01e-05	0.000237	CcSEcCtD
Risperidone—Urinary tract infection—Doxorubicin—pancreatic cancer	7.01e-05	0.000237	CcSEcCtD
Risperidone—Hepatitis—Epirubicin—pancreatic cancer	7e-05	0.000236	CcSEcCtD
Risperidone—Haemorrhage—Epirubicin—pancreatic cancer	7e-05	0.000236	CcSEcCtD
Risperidone—Diarrhoea—Fluorouracil—pancreatic cancer	6.99e-05	0.000236	CcSEcCtD
Risperidone—Hypoaesthesia—Epirubicin—pancreatic cancer	6.97e-05	0.000235	CcSEcCtD
Risperidone—Pharyngitis—Epirubicin—pancreatic cancer	6.95e-05	0.000235	CcSEcCtD
Risperidone—Sweating—Doxorubicin—pancreatic cancer	6.92e-05	0.000234	CcSEcCtD
Risperidone—Urinary tract disorder—Epirubicin—pancreatic cancer	6.91e-05	0.000233	CcSEcCtD
Risperidone—Oedema peripheral—Epirubicin—pancreatic cancer	6.9e-05	0.000233	CcSEcCtD
Risperidone—Hypotension—Docetaxel—pancreatic cancer	6.89e-05	0.000233	CcSEcCtD
Risperidone—Haematuria—Doxorubicin—pancreatic cancer	6.88e-05	0.000232	CcSEcCtD
Risperidone—Connective tissue disorder—Epirubicin—pancreatic cancer	6.88e-05	0.000232	CcSEcCtD
Risperidone—Urethral disorder—Epirubicin—pancreatic cancer	6.86e-05	0.000232	CcSEcCtD
Risperidone—Hepatobiliary disease—Doxorubicin—pancreatic cancer	6.82e-05	0.00023	CcSEcCtD
Risperidone—Epistaxis—Doxorubicin—pancreatic cancer	6.81e-05	0.00023	CcSEcCtD
Risperidone—Vomiting—Irinotecan—pancreatic cancer	6.78e-05	0.000229	CcSEcCtD
Risperidone—Sinusitis—Doxorubicin—pancreatic cancer	6.77e-05	0.000229	CcSEcCtD
Risperidone—Dizziness—Fluorouracil—pancreatic cancer	6.76e-05	0.000228	CcSEcCtD
Risperidone—Visual impairment—Epirubicin—pancreatic cancer	6.75e-05	0.000228	CcSEcCtD
Risperidone—Agranulocytosis—Doxorubicin—pancreatic cancer	6.73e-05	0.000227	CcSEcCtD
Risperidone—Rash—Irinotecan—pancreatic cancer	6.73e-05	0.000227	CcSEcCtD
Risperidone—Dermatitis—Irinotecan—pancreatic cancer	6.72e-05	0.000227	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	6.72e-05	0.000227	CcSEcCtD
Risperidone—Headache—Irinotecan—pancreatic cancer	6.68e-05	0.000226	CcSEcCtD
Risperidone—Insomnia—Docetaxel—pancreatic cancer	6.67e-05	0.000225	CcSEcCtD
Risperidone—Paraesthesia—Docetaxel—pancreatic cancer	6.62e-05	0.000224	CcSEcCtD
Risperidone—Erythema multiforme—Epirubicin—pancreatic cancer	6.62e-05	0.000223	CcSEcCtD
Risperidone—Vomiting—Gemcitabine—pancreatic cancer	6.61e-05	0.000223	CcSEcCtD
Risperidone—Bradycardia—Doxorubicin—pancreatic cancer	6.59e-05	0.000223	CcSEcCtD
Risperidone—Dyspnoea—Docetaxel—pancreatic cancer	6.57e-05	0.000222	CcSEcCtD
Risperidone—Somnolence—Docetaxel—pancreatic cancer	6.56e-05	0.000221	CcSEcCtD
Risperidone—Rash—Gemcitabine—pancreatic cancer	6.55e-05	0.000221	CcSEcCtD
Risperidone—Dermatitis—Gemcitabine—pancreatic cancer	6.55e-05	0.000221	CcSEcCtD
Risperidone—Eye disorder—Epirubicin—pancreatic cancer	6.54e-05	0.000221	CcSEcCtD
Risperidone—Tinnitus—Epirubicin—pancreatic cancer	6.53e-05	0.00022	CcSEcCtD
Risperidone—Haemoglobin—Doxorubicin—pancreatic cancer	6.51e-05	0.00022	CcSEcCtD
Risperidone—Headache—Gemcitabine—pancreatic cancer	6.51e-05	0.00022	CcSEcCtD
Risperidone—Cardiac disorder—Epirubicin—pancreatic cancer	6.5e-05	0.000219	CcSEcCtD
Risperidone—Flushing—Epirubicin—pancreatic cancer	6.5e-05	0.000219	CcSEcCtD
Risperidone—Vomiting—Fluorouracil—pancreatic cancer	6.5e-05	0.000219	CcSEcCtD
Risperidone—Rhinitis—Doxorubicin—pancreatic cancer	6.49e-05	0.000219	CcSEcCtD
Risperidone—Dyspepsia—Docetaxel—pancreatic cancer	6.49e-05	0.000219	CcSEcCtD
Risperidone—Hepatitis—Doxorubicin—pancreatic cancer	6.48e-05	0.000219	CcSEcCtD
Risperidone—Haemorrhage—Doxorubicin—pancreatic cancer	6.48e-05	0.000219	CcSEcCtD
Risperidone—Hypoaesthesia—Doxorubicin—pancreatic cancer	6.45e-05	0.000218	CcSEcCtD
Risperidone—Rash—Fluorouracil—pancreatic cancer	6.44e-05	0.000217	CcSEcCtD
Risperidone—Dermatitis—Fluorouracil—pancreatic cancer	6.44e-05	0.000217	CcSEcCtD
Risperidone—Pharyngitis—Doxorubicin—pancreatic cancer	6.43e-05	0.000217	CcSEcCtD
Risperidone—Decreased appetite—Docetaxel—pancreatic cancer	6.41e-05	0.000216	CcSEcCtD
Risperidone—Headache—Fluorouracil—pancreatic cancer	6.4e-05	0.000216	CcSEcCtD
Risperidone—Urinary tract disorder—Doxorubicin—pancreatic cancer	6.4e-05	0.000216	CcSEcCtD
Risperidone—Oedema peripheral—Doxorubicin—pancreatic cancer	6.38e-05	0.000215	CcSEcCtD
Risperidone—Gastrointestinal disorder—Docetaxel—pancreatic cancer	6.37e-05	0.000215	CcSEcCtD
Risperidone—Connective tissue disorder—Doxorubicin—pancreatic cancer	6.37e-05	0.000215	CcSEcCtD
Risperidone—Fatigue—Docetaxel—pancreatic cancer	6.36e-05	0.000215	CcSEcCtD
Risperidone—Angiopathy—Epirubicin—pancreatic cancer	6.35e-05	0.000214	CcSEcCtD
Risperidone—Urethral disorder—Doxorubicin—pancreatic cancer	6.35e-05	0.000214	CcSEcCtD
Risperidone—Nausea—Irinotecan—pancreatic cancer	6.34e-05	0.000214	CcSEcCtD
Risperidone—Immune system disorder—Epirubicin—pancreatic cancer	6.32e-05	0.000213	CcSEcCtD
Risperidone—Mediastinal disorder—Epirubicin—pancreatic cancer	6.31e-05	0.000213	CcSEcCtD
Risperidone—Constipation—Docetaxel—pancreatic cancer	6.31e-05	0.000213	CcSEcCtD
Risperidone—Pain—Docetaxel—pancreatic cancer	6.31e-05	0.000213	CcSEcCtD
Risperidone—Chills—Epirubicin—pancreatic cancer	6.28e-05	0.000212	CcSEcCtD
Risperidone—Arrhythmia—Epirubicin—pancreatic cancer	6.25e-05	0.000211	CcSEcCtD
Risperidone—Visual impairment—Doxorubicin—pancreatic cancer	6.24e-05	0.000211	CcSEcCtD
Risperidone—Alopecia—Epirubicin—pancreatic cancer	6.19e-05	0.000209	CcSEcCtD
Risperidone—Nausea—Gemcitabine—pancreatic cancer	6.17e-05	0.000208	CcSEcCtD
Risperidone—Mental disorder—Epirubicin—pancreatic cancer	6.13e-05	0.000207	CcSEcCtD
Risperidone—Erythema multiforme—Doxorubicin—pancreatic cancer	6.13e-05	0.000207	CcSEcCtD
Risperidone—Erythema—Epirubicin—pancreatic cancer	6.09e-05	0.000206	CcSEcCtD
Risperidone—Malnutrition—Epirubicin—pancreatic cancer	6.09e-05	0.000206	CcSEcCtD
Risperidone—Feeling abnormal—Docetaxel—pancreatic cancer	6.08e-05	0.000205	CcSEcCtD
Risperidone—Nausea—Fluorouracil—pancreatic cancer	6.07e-05	0.000205	CcSEcCtD
Risperidone—Eye disorder—Doxorubicin—pancreatic cancer	6.05e-05	0.000204	CcSEcCtD
Risperidone—Tinnitus—Doxorubicin—pancreatic cancer	6.04e-05	0.000204	CcSEcCtD
Risperidone—Gastrointestinal pain—Docetaxel—pancreatic cancer	6.03e-05	0.000204	CcSEcCtD
Risperidone—Flushing—Doxorubicin—pancreatic cancer	6.01e-05	0.000203	CcSEcCtD
Risperidone—Cardiac disorder—Doxorubicin—pancreatic cancer	6.01e-05	0.000203	CcSEcCtD
Risperidone—Flatulence—Epirubicin—pancreatic cancer	6.01e-05	0.000203	CcSEcCtD
Risperidone—Tension—Epirubicin—pancreatic cancer	5.98e-05	0.000202	CcSEcCtD
Risperidone—Dysgeusia—Epirubicin—pancreatic cancer	5.97e-05	0.000201	CcSEcCtD
Risperidone—Nervousness—Epirubicin—pancreatic cancer	5.92e-05	0.0002	CcSEcCtD
Risperidone—Back pain—Epirubicin—pancreatic cancer	5.9e-05	0.000199	CcSEcCtD
Risperidone—Angiopathy—Doxorubicin—pancreatic cancer	5.88e-05	0.000198	CcSEcCtD
Risperidone—Muscle spasms—Epirubicin—pancreatic cancer	5.86e-05	0.000198	CcSEcCtD
Risperidone—Immune system disorder—Doxorubicin—pancreatic cancer	5.85e-05	0.000198	CcSEcCtD
Risperidone—Mediastinal disorder—Doxorubicin—pancreatic cancer	5.84e-05	0.000197	CcSEcCtD
Risperidone—Abdominal pain—Docetaxel—pancreatic cancer	5.83e-05	0.000197	CcSEcCtD
Risperidone—Body temperature increased—Docetaxel—pancreatic cancer	5.83e-05	0.000197	CcSEcCtD
Risperidone—Chills—Doxorubicin—pancreatic cancer	5.81e-05	0.000196	CcSEcCtD
Risperidone—Arrhythmia—Doxorubicin—pancreatic cancer	5.79e-05	0.000195	CcSEcCtD
Risperidone—Vision blurred—Epirubicin—pancreatic cancer	5.74e-05	0.000194	CcSEcCtD
Risperidone—Alopecia—Doxorubicin—pancreatic cancer	5.72e-05	0.000193	CcSEcCtD
Risperidone—Mental disorder—Doxorubicin—pancreatic cancer	5.68e-05	0.000192	CcSEcCtD
Risperidone—Ill-defined disorder—Epirubicin—pancreatic cancer	5.65e-05	0.000191	CcSEcCtD
Risperidone—Erythema—Doxorubicin—pancreatic cancer	5.64e-05	0.00019	CcSEcCtD
Risperidone—Malnutrition—Doxorubicin—pancreatic cancer	5.64e-05	0.00019	CcSEcCtD
Risperidone—Anaemia—Epirubicin—pancreatic cancer	5.63e-05	0.00019	CcSEcCtD
Risperidone—Agitation—Epirubicin—pancreatic cancer	5.6e-05	0.000189	CcSEcCtD
Risperidone—Flatulence—Doxorubicin—pancreatic cancer	5.56e-05	0.000188	CcSEcCtD
Risperidone—Tension—Doxorubicin—pancreatic cancer	5.53e-05	0.000187	CcSEcCtD
Risperidone—Dysgeusia—Doxorubicin—pancreatic cancer	5.52e-05	0.000186	CcSEcCtD
Risperidone—Malaise—Epirubicin—pancreatic cancer	5.5e-05	0.000186	CcSEcCtD
Risperidone—Nervousness—Doxorubicin—pancreatic cancer	5.48e-05	0.000185	CcSEcCtD
Risperidone—Vertigo—Epirubicin—pancreatic cancer	5.48e-05	0.000185	CcSEcCtD
Risperidone—Syncope—Epirubicin—pancreatic cancer	5.47e-05	0.000185	CcSEcCtD
Risperidone—Leukopenia—Epirubicin—pancreatic cancer	5.46e-05	0.000184	CcSEcCtD
Risperidone—Back pain—Doxorubicin—pancreatic cancer	5.45e-05	0.000184	CcSEcCtD
Risperidone—Hypersensitivity—Docetaxel—pancreatic cancer	5.43e-05	0.000183	CcSEcCtD
Risperidone—Muscle spasms—Doxorubicin—pancreatic cancer	5.42e-05	0.000183	CcSEcCtD
Risperidone—Palpitations—Epirubicin—pancreatic cancer	5.39e-05	0.000182	CcSEcCtD
Risperidone—Loss of consciousness—Epirubicin—pancreatic cancer	5.36e-05	0.000181	CcSEcCtD
Risperidone—Cough—Epirubicin—pancreatic cancer	5.32e-05	0.00018	CcSEcCtD
Risperidone—Vision blurred—Doxorubicin—pancreatic cancer	5.31e-05	0.000179	CcSEcCtD
Risperidone—Asthenia—Docetaxel—pancreatic cancer	5.29e-05	0.000179	CcSEcCtD
Risperidone—Convulsion—Epirubicin—pancreatic cancer	5.28e-05	0.000178	CcSEcCtD
Risperidone—Hypertension—Epirubicin—pancreatic cancer	5.26e-05	0.000178	CcSEcCtD
Risperidone—Ill-defined disorder—Doxorubicin—pancreatic cancer	5.23e-05	0.000177	CcSEcCtD
Risperidone—Pruritus—Docetaxel—pancreatic cancer	5.22e-05	0.000176	CcSEcCtD
Risperidone—Anaemia—Doxorubicin—pancreatic cancer	5.21e-05	0.000176	CcSEcCtD
Risperidone—Myalgia—Epirubicin—pancreatic cancer	5.19e-05	0.000175	CcSEcCtD
Risperidone—Chest pain—Epirubicin—pancreatic cancer	5.19e-05	0.000175	CcSEcCtD
Risperidone—Arthralgia—Epirubicin—pancreatic cancer	5.19e-05	0.000175	CcSEcCtD
Risperidone—Agitation—Doxorubicin—pancreatic cancer	5.18e-05	0.000175	CcSEcCtD
Risperidone—Anxiety—Epirubicin—pancreatic cancer	5.17e-05	0.000175	CcSEcCtD
Risperidone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	5.15e-05	0.000174	CcSEcCtD
Risperidone—Discomfort—Epirubicin—pancreatic cancer	5.13e-05	0.000173	CcSEcCtD
Risperidone—Malaise—Doxorubicin—pancreatic cancer	5.09e-05	0.000172	CcSEcCtD
Risperidone—Dry mouth—Epirubicin—pancreatic cancer	5.07e-05	0.000171	CcSEcCtD
Risperidone—Vertigo—Doxorubicin—pancreatic cancer	5.07e-05	0.000171	CcSEcCtD
Risperidone—Syncope—Doxorubicin—pancreatic cancer	5.06e-05	0.000171	CcSEcCtD
Risperidone—Leukopenia—Doxorubicin—pancreatic cancer	5.05e-05	0.00017	CcSEcCtD
Risperidone—Diarrhoea—Docetaxel—pancreatic cancer	5.05e-05	0.00017	CcSEcCtD
Risperidone—Confusional state—Epirubicin—pancreatic cancer	5.02e-05	0.000169	CcSEcCtD
Risperidone—Palpitations—Doxorubicin—pancreatic cancer	4.98e-05	0.000168	CcSEcCtD
Risperidone—Oedema—Epirubicin—pancreatic cancer	4.97e-05	0.000168	CcSEcCtD
Risperidone—Anaphylactic shock—Epirubicin—pancreatic cancer	4.97e-05	0.000168	CcSEcCtD
Risperidone—Loss of consciousness—Doxorubicin—pancreatic cancer	4.96e-05	0.000167	CcSEcCtD
Risperidone—Infection—Epirubicin—pancreatic cancer	4.94e-05	0.000167	CcSEcCtD
Risperidone—Cough—Doxorubicin—pancreatic cancer	4.92e-05	0.000166	CcSEcCtD
Risperidone—Shock—Epirubicin—pancreatic cancer	4.89e-05	0.000165	CcSEcCtD
Risperidone—Convulsion—Doxorubicin—pancreatic cancer	4.89e-05	0.000165	CcSEcCtD
Risperidone—Nervous system disorder—Epirubicin—pancreatic cancer	4.88e-05	0.000165	CcSEcCtD
Risperidone—Dizziness—Docetaxel—pancreatic cancer	4.88e-05	0.000165	CcSEcCtD
Risperidone—Thrombocytopenia—Epirubicin—pancreatic cancer	4.87e-05	0.000164	CcSEcCtD
Risperidone—Hypertension—Doxorubicin—pancreatic cancer	4.87e-05	0.000164	CcSEcCtD
Risperidone—Tachycardia—Epirubicin—pancreatic cancer	4.85e-05	0.000164	CcSEcCtD
Risperidone—Skin disorder—Epirubicin—pancreatic cancer	4.83e-05	0.000163	CcSEcCtD
Risperidone—Hyperhidrosis—Epirubicin—pancreatic cancer	4.81e-05	0.000162	CcSEcCtD
Risperidone—Chest pain—Doxorubicin—pancreatic cancer	4.8e-05	0.000162	CcSEcCtD
Risperidone—Myalgia—Doxorubicin—pancreatic cancer	4.8e-05	0.000162	CcSEcCtD
Risperidone—Arthralgia—Doxorubicin—pancreatic cancer	4.8e-05	0.000162	CcSEcCtD
Risperidone—Anxiety—Doxorubicin—pancreatic cancer	4.78e-05	0.000162	CcSEcCtD
Risperidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	4.77e-05	0.000161	CcSEcCtD
Risperidone—Discomfort—Doxorubicin—pancreatic cancer	4.74e-05	0.00016	CcSEcCtD
Risperidone—Anorexia—Epirubicin—pancreatic cancer	4.74e-05	0.00016	CcSEcCtD
Risperidone—Dry mouth—Doxorubicin—pancreatic cancer	4.7e-05	0.000159	CcSEcCtD
Risperidone—Vomiting—Docetaxel—pancreatic cancer	4.69e-05	0.000158	CcSEcCtD
Risperidone—Rash—Docetaxel—pancreatic cancer	4.65e-05	0.000157	CcSEcCtD
Risperidone—Hypotension—Epirubicin—pancreatic cancer	4.65e-05	0.000157	CcSEcCtD
Risperidone—Dermatitis—Docetaxel—pancreatic cancer	4.65e-05	0.000157	CcSEcCtD
Risperidone—Confusional state—Doxorubicin—pancreatic cancer	4.64e-05	0.000157	CcSEcCtD
Risperidone—Headache—Docetaxel—pancreatic cancer	4.62e-05	0.000156	CcSEcCtD
Risperidone—Oedema—Doxorubicin—pancreatic cancer	4.6e-05	0.000155	CcSEcCtD
Risperidone—Anaphylactic shock—Doxorubicin—pancreatic cancer	4.6e-05	0.000155	CcSEcCtD
Risperidone—Infection—Doxorubicin—pancreatic cancer	4.57e-05	0.000154	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	4.53e-05	0.000153	CcSEcCtD
Risperidone—Shock—Doxorubicin—pancreatic cancer	4.53e-05	0.000153	CcSEcCtD
Risperidone—Nervous system disorder—Doxorubicin—pancreatic cancer	4.51e-05	0.000152	CcSEcCtD
Risperidone—Thrombocytopenia—Doxorubicin—pancreatic cancer	4.51e-05	0.000152	CcSEcCtD
Risperidone—Insomnia—Epirubicin—pancreatic cancer	4.5e-05	0.000152	CcSEcCtD
Risperidone—Tachycardia—Doxorubicin—pancreatic cancer	4.49e-05	0.000152	CcSEcCtD
Risperidone—Skin disorder—Doxorubicin—pancreatic cancer	4.47e-05	0.000151	CcSEcCtD
Risperidone—Paraesthesia—Epirubicin—pancreatic cancer	4.47e-05	0.000151	CcSEcCtD
Risperidone—Hyperhidrosis—Doxorubicin—pancreatic cancer	4.45e-05	0.00015	CcSEcCtD
Risperidone—Dyspnoea—Epirubicin—pancreatic cancer	4.43e-05	0.00015	CcSEcCtD
Risperidone—Somnolence—Epirubicin—pancreatic cancer	4.42e-05	0.000149	CcSEcCtD
Risperidone—Anorexia—Doxorubicin—pancreatic cancer	4.39e-05	0.000148	CcSEcCtD
Risperidone—Nausea—Docetaxel—pancreatic cancer	4.38e-05	0.000148	CcSEcCtD
Risperidone—Dyspepsia—Epirubicin—pancreatic cancer	4.38e-05	0.000148	CcSEcCtD
Risperidone—Decreased appetite—Epirubicin—pancreatic cancer	4.32e-05	0.000146	CcSEcCtD
Risperidone—Hypotension—Doxorubicin—pancreatic cancer	4.3e-05	0.000145	CcSEcCtD
Risperidone—Gastrointestinal disorder—Epirubicin—pancreatic cancer	4.29e-05	0.000145	CcSEcCtD
Risperidone—Fatigue—Epirubicin—pancreatic cancer	4.29e-05	0.000145	CcSEcCtD
Risperidone—Constipation—Epirubicin—pancreatic cancer	4.25e-05	0.000144	CcSEcCtD
Risperidone—Pain—Epirubicin—pancreatic cancer	4.25e-05	0.000144	CcSEcCtD
Risperidone—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	4.19e-05	0.000142	CcSEcCtD
Risperidone—Insomnia—Doxorubicin—pancreatic cancer	4.16e-05	0.000141	CcSEcCtD
Risperidone—Paraesthesia—Doxorubicin—pancreatic cancer	4.13e-05	0.00014	CcSEcCtD
Risperidone—Dyspnoea—Doxorubicin—pancreatic cancer	4.1e-05	0.000139	CcSEcCtD
Risperidone—Feeling abnormal—Epirubicin—pancreatic cancer	4.1e-05	0.000138	CcSEcCtD
Risperidone—Somnolence—Doxorubicin—pancreatic cancer	4.09e-05	0.000138	CcSEcCtD
Risperidone—Gastrointestinal pain—Epirubicin—pancreatic cancer	4.07e-05	0.000137	CcSEcCtD
Risperidone—Dyspepsia—Doxorubicin—pancreatic cancer	4.05e-05	0.000137	CcSEcCtD
Risperidone—Decreased appetite—Doxorubicin—pancreatic cancer	4e-05	0.000135	CcSEcCtD
Risperidone—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	3.97e-05	0.000134	CcSEcCtD
Risperidone—Fatigue—Doxorubicin—pancreatic cancer	3.97e-05	0.000134	CcSEcCtD
Risperidone—Urticaria—Epirubicin—pancreatic cancer	3.95e-05	0.000133	CcSEcCtD
Risperidone—Pain—Doxorubicin—pancreatic cancer	3.94e-05	0.000133	CcSEcCtD
Risperidone—Constipation—Doxorubicin—pancreatic cancer	3.94e-05	0.000133	CcSEcCtD
Risperidone—Body temperature increased—Epirubicin—pancreatic cancer	3.93e-05	0.000133	CcSEcCtD
Risperidone—Abdominal pain—Epirubicin—pancreatic cancer	3.93e-05	0.000133	CcSEcCtD
Risperidone—Feeling abnormal—Doxorubicin—pancreatic cancer	3.79e-05	0.000128	CcSEcCtD
Risperidone—Gastrointestinal pain—Doxorubicin—pancreatic cancer	3.76e-05	0.000127	CcSEcCtD
Risperidone—Hypersensitivity—Epirubicin—pancreatic cancer	3.66e-05	0.000124	CcSEcCtD
Risperidone—Urticaria—Doxorubicin—pancreatic cancer	3.66e-05	0.000123	CcSEcCtD
Risperidone—Abdominal pain—Doxorubicin—pancreatic cancer	3.64e-05	0.000123	CcSEcCtD
Risperidone—Body temperature increased—Doxorubicin—pancreatic cancer	3.64e-05	0.000123	CcSEcCtD
Risperidone—Asthenia—Epirubicin—pancreatic cancer	3.57e-05	0.00012	CcSEcCtD
Risperidone—Pruritus—Epirubicin—pancreatic cancer	3.52e-05	0.000119	CcSEcCtD
Risperidone—Diarrhoea—Epirubicin—pancreatic cancer	3.4e-05	0.000115	CcSEcCtD
Risperidone—Hypersensitivity—Doxorubicin—pancreatic cancer	3.39e-05	0.000114	CcSEcCtD
Risperidone—Asthenia—Doxorubicin—pancreatic cancer	3.3e-05	0.000111	CcSEcCtD
Risperidone—Dizziness—Epirubicin—pancreatic cancer	3.29e-05	0.000111	CcSEcCtD
Risperidone—Pruritus—Doxorubicin—pancreatic cancer	3.26e-05	0.00011	CcSEcCtD
Risperidone—Vomiting—Epirubicin—pancreatic cancer	3.16e-05	0.000107	CcSEcCtD
Risperidone—Diarrhoea—Doxorubicin—pancreatic cancer	3.15e-05	0.000106	CcSEcCtD
Risperidone—Rash—Epirubicin—pancreatic cancer	3.14e-05	0.000106	CcSEcCtD
Risperidone—Dermatitis—Epirubicin—pancreatic cancer	3.13e-05	0.000106	CcSEcCtD
Risperidone—Headache—Epirubicin—pancreatic cancer	3.12e-05	0.000105	CcSEcCtD
Risperidone—Dizziness—Doxorubicin—pancreatic cancer	3.04e-05	0.000103	CcSEcCtD
Risperidone—Nausea—Epirubicin—pancreatic cancer	2.95e-05	9.97e-05	CcSEcCtD
Risperidone—Vomiting—Doxorubicin—pancreatic cancer	2.93e-05	9.88e-05	CcSEcCtD
Risperidone—Rash—Doxorubicin—pancreatic cancer	2.9e-05	9.8e-05	CcSEcCtD
Risperidone—Dermatitis—Doxorubicin—pancreatic cancer	2.9e-05	9.79e-05	CcSEcCtD
Risperidone—Headache—Doxorubicin—pancreatic cancer	2.88e-05	9.73e-05	CcSEcCtD
Risperidone—Nausea—Doxorubicin—pancreatic cancer	2.73e-05	9.23e-05	CcSEcCtD
Risperidone—ADRA1A—Signaling Pathways—PIK3CB—pancreatic cancer	4.71e-06	3.17e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—CTNNB1—pancreatic cancer	4.7e-06	3.16e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—CXCL8—pancreatic cancer	4.7e-06	3.16e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling by GPCR—AKT1—pancreatic cancer	4.69e-06	3.15e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—MMP9—pancreatic cancer	4.68e-06	3.15e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling by GPCR—AKT1—pancreatic cancer	4.67e-06	3.14e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling by GPCR—HRAS—pancreatic cancer	4.66e-06	3.14e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—PTEN—pancreatic cancer	4.65e-06	3.13e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—MYC—pancreatic cancer	4.65e-06	3.12e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—TGFB1—pancreatic cancer	4.64e-06	3.12e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—CXCL8—pancreatic cancer	4.62e-06	3.11e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—SRC—pancreatic cancer	4.62e-06	3.11e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—CXCL8—pancreatic cancer	4.61e-06	3.1e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—MMP9—pancreatic cancer	4.61e-06	3.1e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—STK11—pancreatic cancer	4.61e-06	3.1e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling by GPCR—HRAS—pancreatic cancer	4.59e-06	3.09e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—MYC—pancreatic cancer	4.59e-06	3.08e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling by GPCR—HRAS—pancreatic cancer	4.58e-06	3.08e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—PTEN—pancreatic cancer	4.58e-06	3.08e-05	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—PIK3CA—pancreatic cancer	4.58e-06	3.08e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—TGFB1—pancreatic cancer	4.57e-06	3.08e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—PPARG—pancreatic cancer	4.56e-06	3.06e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—KRAS—pancreatic cancer	4.55e-06	3.06e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—PIK3CA—pancreatic cancer	4.55e-06	3.06e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—EGFR—pancreatic cancer	4.55e-06	3.06e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling by GPCR—AKT1—pancreatic cancer	4.54e-06	3.05e-05	CbGpPWpGaD
Risperidone—DRD2—GPCR downstream signaling—AKT1—pancreatic cancer	4.54e-06	3.05e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—CXCL8—pancreatic cancer	4.52e-06	3.04e-05	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—PTEN—pancreatic cancer	4.52e-06	3.04e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—PIK3CA—pancreatic cancer	4.51e-06	3.03e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—VEGFA—pancreatic cancer	4.5e-06	3.03e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling by GPCR—HRAS—pancreatic cancer	4.49e-06	3.02e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—CASP3—pancreatic cancer	4.49e-06	3.02e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—EGFR—pancreatic cancer	4.48e-06	3.02e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling by GPCR—AKT1—pancreatic cancer	4.47e-06	3e-05	CbGpPWpGaD
Risperidone—HTR2A—GPCR downstream signaling—AKT1—pancreatic cancer	4.46e-06	3e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—SRC—pancreatic cancer	4.46e-06	3e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—STAT3—pancreatic cancer	4.45e-06	3e-05	CbGpPWpGaD
Risperidone—HRH1—GPCR downstream signaling—AKT1—pancreatic cancer	4.45e-06	2.99e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—PIK3CA—pancreatic cancer	4.45e-06	2.99e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	4.45e-06	2.99e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—NRAS—pancreatic cancer	4.44e-06	2.99e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—SRC—pancreatic cancer	4.44e-06	2.98e-05	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—TP53—pancreatic cancer	4.43e-06	2.98e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—CASP3—pancreatic cancer	4.42e-06	2.97e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—CASP3—pancreatic cancer	4.41e-06	2.97e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—TP53—pancreatic cancer	4.4e-06	2.96e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—PIK3CA—pancreatic cancer	4.38e-06	2.95e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—CCND1—pancreatic cancer	4.37e-06	2.94e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—PIK3CB—pancreatic cancer	4.37e-06	2.94e-05	CbGpPWpGaD
Risperidone—ADRA1A—GPCR downstream signaling—AKT1—pancreatic cancer	4.37e-06	2.94e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—VEGFA—pancreatic cancer	4.34e-06	2.92e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—CTNNB1—pancreatic cancer	4.33e-06	2.91e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—CASP3—pancreatic cancer	4.33e-06	2.91e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—VEGFA—pancreatic cancer	4.32e-06	2.91e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—SRC—pancreatic cancer	4.31e-06	2.9e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—TP53—pancreatic cancer	4.31e-06	2.9e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—CCND1—pancreatic cancer	4.3e-06	2.89e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—STAT3—pancreatic cancer	4.3e-06	2.89e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—CCND1—pancreatic cancer	4.29e-06	2.89e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—KRAS—pancreatic cancer	4.29e-06	2.89e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PPARG—pancreatic cancer	4.29e-06	2.89e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—NRAS—pancreatic cancer	4.29e-06	2.88e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—STAT3—pancreatic cancer	4.28e-06	2.88e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—NRAS—pancreatic cancer	4.27e-06	2.87e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—CTNNB1—pancreatic cancer	4.26e-06	2.87e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—CTNNB1—pancreatic cancer	4.25e-06	2.86e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—SRC—pancreatic cancer	4.25e-06	2.86e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—MMP9—pancreatic cancer	4.25e-06	2.86e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—TP53—pancreatic cancer	4.24e-06	2.85e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—KRAS—pancreatic cancer	4.24e-06	2.85e-05	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—HRAS—pancreatic cancer	4.24e-06	2.85e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—PTEN—pancreatic cancer	4.22e-06	2.84e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—CCND1—pancreatic cancer	4.21e-06	2.83e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—HRAS—pancreatic cancer	4.21e-06	2.83e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CXCL8—pancreatic cancer	4.2e-06	2.83e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—VEGFA—pancreatic cancer	4.2e-06	2.83e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—PIK3CA—pancreatic cancer	4.18e-06	2.81e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—MMP9—pancreatic cancer	4.18e-06	2.81e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—HRAS—pancreatic cancer	4.18e-06	2.81e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—CTNNB1—pancreatic cancer	4.17e-06	2.81e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—MMP9—pancreatic cancer	4.17e-06	2.8e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—STAT3—pancreatic cancer	4.16e-06	2.8e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—PTEN—pancreatic cancer	4.15e-06	2.79e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—NRAS—pancreatic cancer	4.15e-06	2.79e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—PIK3CD—pancreatic cancer	4.15e-06	2.79e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—PTEN—pancreatic cancer	4.15e-06	2.79e-05	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—PTEN—pancreatic cancer	4.14e-06	2.79e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—MYC—pancreatic cancer	4.14e-06	2.78e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—VEGFA—pancreatic cancer	4.14e-06	2.78e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—TGFB1—pancreatic cancer	4.13e-06	2.78e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—HRAS—pancreatic cancer	4.12e-06	2.77e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling by GPCR—AKT1—pancreatic cancer	4.12e-06	2.77e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—STAT3—pancreatic cancer	4.1e-06	2.75e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—MMP9—pancreatic cancer	4.09e-06	2.75e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—NRAS—pancreatic cancer	4.09e-06	2.75e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—PTEN—pancreatic cancer	4.07e-06	2.74e-05	CbGpPWpGaD
Risperidone—ADRA2A—GPCR downstream signaling—AKT1—pancreatic cancer	4.06e-06	2.73e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—HRAS—pancreatic cancer	4.05e-06	2.73e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling by GPCR—AKT1—pancreatic cancer	4.05e-06	2.73e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—EGFR—pancreatic cancer	4.05e-06	2.72e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—TP53—pancreatic cancer	4.05e-06	2.72e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling by GPCR—AKT1—pancreatic cancer	4.04e-06	2.72e-05	CbGpPWpGaD
Risperidone—CYP3A7—Metabolism—PIK3CA—pancreatic cancer	4.04e-06	2.72e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CASP3—pancreatic cancer	4.02e-06	2.71e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—MYC—pancreatic cancer	4e-06	2.69e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—TGFB1—pancreatic cancer	3.99e-06	2.68e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—MYC—pancreatic cancer	3.98e-06	2.67e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling by GPCR—AKT1—pancreatic cancer	3.97e-06	2.67e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—TGFB1—pancreatic cancer	3.97e-06	2.67e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—TYMS—pancreatic cancer	3.96e-06	2.66e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—PIK3CA—pancreatic cancer	3.94e-06	2.65e-05	CbGpPWpGaD
Risperidone—ADRA2C—Metabolism—PIK3CA—pancreatic cancer	3.93e-06	2.64e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CCND1—pancreatic cancer	3.92e-06	2.63e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—SRC—pancreatic cancer	3.92e-06	2.63e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	3.91e-06	2.63e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—EGFR—pancreatic cancer	3.91e-06	2.63e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—PIK3CA—pancreatic cancer	3.89e-06	2.62e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—EGFR—pancreatic cancer	3.89e-06	2.61e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—CTNNB1—pancreatic cancer	3.88e-06	2.61e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—HRAS—pancreatic cancer	3.87e-06	2.6e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—MYC—pancreatic cancer	3.87e-06	2.6e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—TGFB1—pancreatic cancer	3.86e-06	2.59e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—SRC—pancreatic cancer	3.85e-06	2.59e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—SRC—pancreatic cancer	3.84e-06	2.58e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—KRAS—pancreatic cancer	3.82e-06	2.57e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—TP53—pancreatic cancer	3.82e-06	2.57e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—VEGFA—pancreatic cancer	3.81e-06	2.56e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—MYC—pancreatic cancer	3.81e-06	2.56e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—MMP9—pancreatic cancer	3.8e-06	2.56e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—TGFB1—pancreatic cancer	3.8e-06	2.55e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—EGFR—pancreatic cancer	3.78e-06	2.54e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—PTEN—pancreatic cancer	3.78e-06	2.54e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—STAT3—pancreatic cancer	3.78e-06	2.54e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—SRC—pancreatic cancer	3.77e-06	2.54e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—NRAS—pancreatic cancer	3.77e-06	2.53e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—TP53—pancreatic cancer	3.77e-06	2.53e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—VEGFA—pancreatic cancer	3.75e-06	2.52e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—VEGFA—pancreatic cancer	3.74e-06	2.52e-05	CbGpPWpGaD
Risperidone—HTR7—Signaling Pathways—AKT1—pancreatic cancer	3.74e-06	2.51e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—EGFR—pancreatic cancer	3.72e-06	2.5e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—STAT3—pancreatic cancer	3.72e-06	2.5e-05	CbGpPWpGaD
Risperidone—HTR1D—Signaling Pathways—AKT1—pancreatic cancer	3.72e-06	2.5e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—STAT3—pancreatic cancer	3.71e-06	2.49e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—NRAS—pancreatic cancer	3.71e-06	2.49e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—NRAS—pancreatic cancer	3.7e-06	2.49e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—KRAS—pancreatic cancer	3.69e-06	2.48e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling by GPCR—AKT1—pancreatic cancer	3.69e-06	2.48e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—VEGFA—pancreatic cancer	3.67e-06	2.47e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—KRAS—pancreatic cancer	3.67e-06	2.47e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—HRAS—pancreatic cancer	3.65e-06	2.45e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—STAT3—pancreatic cancer	3.64e-06	2.45e-05	CbGpPWpGaD
Risperidone—HTR1B—Signaling Pathways—AKT1—pancreatic cancer	3.64e-06	2.45e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—NRAS—pancreatic cancer	3.63e-06	2.44e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—PIK3CB—pancreatic cancer	3.62e-06	2.43e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—HRAS—pancreatic cancer	3.6e-06	2.42e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—PTGS2—pancreatic cancer	3.58e-06	2.41e-05	CbGpPWpGaD
Risperidone—DRD4—Signaling Pathways—AKT1—pancreatic cancer	3.58e-06	2.41e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—KRAS—pancreatic cancer	3.57e-06	2.4e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—KRAS—pancreatic cancer	3.52e-06	2.36e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—PIK3CA—pancreatic cancer	3.51e-06	2.36e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—MYC—pancreatic cancer	3.51e-06	2.36e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—SRC—pancreatic cancer	3.5e-06	2.36e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—TGFB1—pancreatic cancer	3.5e-06	2.35e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—MYC—pancreatic cancer	3.45e-06	2.32e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—MYC—pancreatic cancer	3.44e-06	2.32e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—TGFB1—pancreatic cancer	3.44e-06	2.32e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—TGFB1—pancreatic cancer	3.44e-06	2.31e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—EGFR—pancreatic cancer	3.43e-06	2.31e-05	CbGpPWpGaD
Risperidone—HTR2B—Signaling Pathways—AKT1—pancreatic cancer	3.42e-06	2.3e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—VEGFA—pancreatic cancer	3.41e-06	2.3e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	3.41e-06	2.29e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—TP53—pancreatic cancer	3.4e-06	2.29e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—PIK3CA—pancreatic cancer	3.39e-06	2.28e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—MYC—pancreatic cancer	3.38e-06	2.27e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—STAT3—pancreatic cancer	3.38e-06	2.27e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PTGS2—pancreatic cancer	3.38e-06	2.27e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—EGFR—pancreatic cancer	3.38e-06	2.27e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—PIK3CA—pancreatic cancer	3.37e-06	2.27e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—TGFB1—pancreatic cancer	3.37e-06	2.27e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—NRAS—pancreatic cancer	3.37e-06	2.27e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—EGFR—pancreatic cancer	3.37e-06	2.27e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—EGFR—pancreatic cancer	3.31e-06	2.22e-05	CbGpPWpGaD
Risperidone—CYP3A7—Metabolism—AKT1—pancreatic cancer	3.3e-06	2.22e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—PIK3CA—pancreatic cancer	3.28e-06	2.21e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—TP53—pancreatic cancer	3.28e-06	2.21e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—TP53—pancreatic cancer	3.26e-06	2.2e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—HRAS—pancreatic cancer	3.25e-06	2.19e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—KRAS—pancreatic cancer	3.24e-06	2.18e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—PIK3CA—pancreatic cancer	3.23e-06	2.17e-05	CbGpPWpGaD
Risperidone—DRD1—Signaling Pathways—AKT1—pancreatic cancer	3.22e-06	2.17e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—APOE—pancreatic cancer	3.22e-06	2.17e-05	CbGpPWpGaD
Risperidone—ADRA2C—Metabolism—AKT1—pancreatic cancer	3.21e-06	2.16e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—KRAS—pancreatic cancer	3.19e-06	2.14e-05	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—PIK3CA—pancreatic cancer	3.19e-06	2.14e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—KRAS—pancreatic cancer	3.18e-06	2.14e-05	CbGpPWpGaD
Risperidone—DRD3—Signaling Pathways—AKT1—pancreatic cancer	3.18e-06	2.14e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—TP53—pancreatic cancer	3.18e-06	2.14e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—MYC—pancreatic cancer	3.14e-06	2.11e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—HRAS—pancreatic cancer	3.14e-06	2.11e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—TGFB1—pancreatic cancer	3.13e-06	2.11e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—PTEN—pancreatic cancer	3.13e-06	2.1e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—TP53—pancreatic cancer	3.13e-06	2.1e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—KRAS—pancreatic cancer	3.12e-06	2.1e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—HRAS—pancreatic cancer	3.12e-06	2.1e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—EGFR—pancreatic cancer	3.07e-06	2.07e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—HRAS—pancreatic cancer	3.04e-06	2.04e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—HRAS—pancreatic cancer	2.99e-06	2.01e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—PIK3CA—pancreatic cancer	2.98e-06	2e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PTEN—pancreatic cancer	2.95e-06	1.98e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—PIK3CA—pancreatic cancer	2.93e-06	1.97e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—PIK3CA—pancreatic cancer	2.92e-06	1.97e-05	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—PIK3CA—pancreatic cancer	2.92e-06	1.96e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	2.91e-06	1.96e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—KRAS—pancreatic cancer	2.9e-06	1.95e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—TP53—pancreatic cancer	2.88e-06	1.94e-05	CbGpPWpGaD
Risperidone—ADRA2B—Signaling Pathways—AKT1—pancreatic cancer	2.87e-06	1.93e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—PIK3CA—pancreatic cancer	2.87e-06	1.93e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—TP53—pancreatic cancer	2.84e-06	1.91e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—TP53—pancreatic cancer	2.83e-06	1.9e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PPARG—pancreatic cancer	2.81e-06	1.89e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—TP53—pancreatic cancer	2.78e-06	1.87e-05	CbGpPWpGaD
Risperidone—HTR1A—Signaling Pathways—AKT1—pancreatic cancer	2.77e-06	1.86e-05	CbGpPWpGaD
Risperidone—HTR2C—Signaling Pathways—AKT1—pancreatic cancer	2.76e-06	1.85e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—HRAS—pancreatic cancer	2.76e-06	1.85e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—HRAS—pancreatic cancer	2.71e-06	1.82e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—HRAS—pancreatic cancer	2.71e-06	1.82e-05	CbGpPWpGaD
Risperidone—ADRA2C—Signaling Pathways—AKT1—pancreatic cancer	2.68e-06	1.8e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—PIK3CA—pancreatic cancer	2.67e-06	1.79e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—HRAS—pancreatic cancer	2.65e-06	1.79e-05	CbGpPWpGaD
Risperidone—ADRA1B—Signaling Pathways—AKT1—pancreatic cancer	2.64e-06	1.77e-05	CbGpPWpGaD
Risperidone—ADRA2A—Metabolism—AKT1—pancreatic cancer	2.6e-06	1.75e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—TP53—pancreatic cancer	2.58e-06	1.73e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	2.56e-06	1.72e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—HRAS—pancreatic cancer	2.47e-06	1.66e-05	CbGpPWpGaD
Risperidone—DRD2—Signaling Pathways—AKT1—pancreatic cancer	2.43e-06	1.64e-05	CbGpPWpGaD
Risperidone—HTR2A—Signaling Pathways—AKT1—pancreatic cancer	2.39e-06	1.61e-05	CbGpPWpGaD
Risperidone—HRH1—Signaling Pathways—AKT1—pancreatic cancer	2.39e-06	1.61e-05	CbGpPWpGaD
Risperidone—CYP3A5—Metabolism—AKT1—pancreatic cancer	2.39e-06	1.61e-05	CbGpPWpGaD
Risperidone—ADRA1A—Signaling Pathways—AKT1—pancreatic cancer	2.34e-06	1.58e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	2.23e-06	1.5e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PTGS2—pancreatic cancer	2.21e-06	1.48e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—PIK3CA—pancreatic cancer	2.2e-06	1.48e-05	CbGpPWpGaD
Risperidone—ADRA2A—Signaling Pathways—AKT1—pancreatic cancer	2.18e-06	1.46e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	2.08e-06	1.4e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PTEN—pancreatic cancer	1.93e-06	1.29e-05	CbGpPWpGaD
Risperidone—ABCB1—Metabolism—AKT1—pancreatic cancer	1.8e-06	1.21e-05	CbGpPWpGaD
Risperidone—CYP2D6—Metabolism—AKT1—pancreatic cancer	1.7e-06	1.14e-05	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	1.36e-06	9.13e-06	CbGpPWpGaD
Risperidone—CYP3A4—Metabolism—AKT1—pancreatic cancer	1.11e-06	7.46e-06	CbGpPWpGaD
